Non-muscle Invasive Bladder Cancer Market
完整報告名稱與涵蓋範圍
Non-muscle Invasive Bladder Cancer Market Size, Share & Trends Analysis Report By Treatment Type (Immunotherapy, Chemotherapy, Targeted Therapy), By Cancer Type (Low Grade Bladder Cancer, High Grade Bladder Cancer), By End-user (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And By Segment Forecasts, 2024-2031
報告摘要
In 2023, the Non-muscle Invasive Bladder Cancer Market worldwide was assessed at USD 2.7 billion. Analysts project it will surge to USD 10.9 billion by 2031, at a CAGR of 19.2% spanning 2024 to 2031.
The Non-muscle Invasive Bladder Cancer sector involves dynamics.
The market's upward path is fueled by rising healthcare spending, technological evolution, and the rising focus on personalized and precision-based approaches in healthcare.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold notable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and rising investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Non-muscle Invasive Bladder Cancer Market Snapshot
Chapter 4. Global Non-muscle Invasive Bladder Cancer Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Treatment Type Estimates & Trend Analysis
5.1. By Treatment Type & Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Treatment Type:
5.2.1. Immunotherapy
5.2.2. Chemotherapy
5.2.3. Targeted Therapy
Chapter 6. Market Segmentation 2: By Cancer Type Estimates & Trend Analysis
6.1. By Cancer Type & Market Share, 2023 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Cancer Type:
6.2.1. Low Grade Bladder Cancer
6.2.2. High Grade Bladder Cancer
Chapter 7. Market Segmentation 3: By End-User Estimates & Trend Analysis
7.1. By End-User & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By End-User:
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
Chapter 8. Non-muscle Invasive Bladder Cancer Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2024-2031
8.1.2. North America Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
8.1.3. North America Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
8.1.4. North America Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2024-2031
8.2.2. Europe Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
8.2.3. Europe Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
8.2.4. Europe Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2024-2031
8.3.2. Asia Pacific Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
8.3.3. Asia Pacific Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
8.3.4. Asia Pacific Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.4. Latin America
8.4.1. Asia Pacific Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2024-2031
8.4.2. Latin America Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
8.4.3. Latin America Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
8.4.4. Latin America Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2024-2031
8.5.2. Middle East & Africa Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
8.5.3. Middle East & Africa Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
8.5.4. Middle East & Africa Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. TARIS Biomedical LLC
9.2.2. Merck & Co., Inc.
9.2.3. Herantis Pharma Oyj
9.2.4. Viventia Bio Inc.
9.2.5. Telormedix SA
9.2.6. Ferring B.V.
9.2.7. Altor BioScience Corporation
9.2.8. Novartis AG
9.2.9. Pfizer Inc.
9.2.10. GSK plc
9.2.11. Sanofi S.A.
9.2.12. Eli Lilly and Company
9.2.13. AstraZeneca
9.2.14. UroGen Pharma
9.2.15. Johnson & Johnson
9.2.16. CG Oncology
9.2.17. ImmunityBio
9.2.18. Theralase Technologies
9.2.19. Protara Therapeutics
9.2.20. enGene
9.2.21. Celgene Corporation
9.2.22. F. Hoffmann-La Roche Ltd
9.2.23. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們